Screener
Corcept Therapeutics CORT Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Corcept Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Accounts payable | (25,885) | 8,149 |
| Accrued research and development expenses | (12,326) | (4,819) |
| Accrued and other liabilities, current and non-current | 24,938 | 1,268 |
| Net cash provided by operating activities | 16,771 | 49,067 |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (2,729) | (161) |
| Proceeds from sales and maturities of marketable securities | 119,312 | 205,536 |
| Purchases of marketable securities | (141,283) | (138,419) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Corcept Therapeutics's operating cash flow?
- Corcept Therapeutics (CORT) reported operating cash flow of $33.54M in Q2 2026.
- How has Corcept Therapeutics's operating cash flow changed year-over-year?
- Corcept Therapeutics's operating cash flow decreased by 23.7% year-over-year, from $43.94M to $33.54M.
- What is the long-term trend for Corcept Therapeutics's operating cash flow?
- Over 4 years (2021 to 2025), Corcept Therapeutics's operating cash flow has grown at a -4.1% compound annual growth rate (CAGR), from $167.89M to $142M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Corcept Therapeutics's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude